Devices, systems, and methods herein relate to performing dialysis to manage a chronic condition such as end-stage renal disease. These systems and methods may allow a patient to orally ingest a potable dialysate and excrete the dialysate via the urinary tract. In some variations, a method may include delivering a dialysate via the esophagus of a patient and draining the dialysate into a bladder of the patient. Delivering the dialysate may further comprise delivering the dialysate through the nasopharynx or oropharynx. Delivering the dialysate through the oropharynx may comprise the patient drinking the dialysate.

Multicomponent copolymers including two or more types of repeat units is presented. In one example, the multicomponent copolymer includes at least one repeat unit AC having a structure (I), at least one repeat unit DC having a structure (II), and at least one repeat unit BC having a structure (III) or (V). The multicomponent copolymer may be cross-linked via a cross-linking agent. A polymer blend including the multicomponent copolymer or a cross-linked copolymer and a second polymer is also provided. The multicomponent copolymer may be a random or a block copolymer. The structural units of the multicomponent copolymers provide improved, tunable properties, such as improved biocompatibility and hydrophilicity, protein fouling, and mechanical properties, to the copolymers and/or the membranes fabricated from the copolymers.

A method for performing a peritoneal dialysis therapy includes performing a plurality of peritoneal dialysis cycles for a patient and tracking an amount of dialysis fluid provided by at least one dialysis fluid pump during the plurality of peritoneal dialysis cycles. The method also includes determining an amount of ultrafiltrate (“UF”) removed from the patient based on the amount of dialysis fluid provided by the at least one dialysis fluid pump. The method further includes updating a UF trend using previous amounts of UF removed from the patient and the amount of UF removed from the patient during the most recent dialysis treatment and generating an alert if the UF trend changes by more than a preset percentage.

The present disclosure relates to semipermeable membranes which are suitable for blood purification, e.g. by hemodialysis, which have an increased ability to remove larger molecules while at the same time effectively retaining albumin. The membranes are characterized by a molecular retention onset (MWRO) of between 9.0 kD and 14.5 kD and a molecular weight cut-off (MWCO) of between 55 kD and 130 kD as determined by dextran sieving curves and can be prepared by industrially feasible processes excluding a treatment with salt before drying. The invention therefore also relates to a process for the production of the membranes and to their use in medical applications.

The present disclosure relates to a dialyzer comprising a bundle of semipermeable hollow fiber membranes which is suitable for blood purification, wherein the dialyzer has an increased ability to remove larger molecules while at the same time it is able to effectively remove small uremic toxins and efficiently retain albumin and larger proteins. The invention also relates to using said dialyzer in hemodialysis.

The present disclosure relates to a hemodialysis membrane for the treatment of restless leg syndrome (RLS), especially in severe and very severe cases and/or in patients which suffer from kidney failure and already receive hemodialysis. The present disclosure therefore also relates to methods of treating restless leg syndrome. The treatment and method encompasses using a hemodialysis membrane which is characterized in that it comprises at least one hydrophobic polymer and at least one hydrophilic polymer and in that it has a MWRO of between 8.5 and 14.0 kD and a MWCO of between 55 kD and 130 kD.

A system for performing a peritoneal dialysis therapy includes at least one dialysis fluid pump, and a logic implementer operable with the at least one dialysis fluid pump to perform a plurality of peritoneal dialysis cycles for a patient. The logic implementer transmits an amount of dialysis fluid provided during the plurality of peritoneal dialysis cycles. A server receives the amount of dialysis fluid provided during the plurality of peritoneal dialysis cycles and determines an amount of ultrafiltration (“UF”) removed from the patient based on the amount of dialysis fluid provided by the at least one dialysis fluid pump. The server also updates a UF trend using previous amounts of UF removed from the patient and the amount of UF removed from the patient during the most recent dialysis treatment and generates an alert if the UF trend changes by more than a preset percentage.

The present disclosure relates to a process for producing a filtration and/or diffusion device, e.g., a capillary dialyzer or an ultrafilter.

Flow capture device and method for removing cells from blood The current invention discloses a blood treating and/or purifying device for removing circulating pathogens, preferably pathogenic cells, more preferably circulating tumor cells from the blood of a patient, a method of producing such a device and method to treat cancer and other diseases caused by virus infection, bacterial infection and parasites infection as well as autoimmune disorders. The described method is an extracorporeal medical therapy, thus can be done also in a hemodialysis system. The current invention also describes a device and an in-situ production method of preparing the device to remove CTC and other pathogens i.e. virus, bacteria or parasites from the bloodstream.

The present disclosure relates to a hemodialysis membrane for the treatment of vascular calcification in hemodialysis patients, especially in chronic hemodialysis patients. The present disclosure further relates to methods of treating vascular calcification in hemodialysis patients, wherein the hemodialysis membrane is characterized in that it comprises at least one hydrophobic polymer and at least one hydrophilic polymer and in that it has a MWRO of between 15 and 20 kD and a MWCO of between 170-320 kD or that the hemodialysis membrane comprises at least one hydrophobic polymer and at least one hydrophilic polymer and has a MWRO of between 8.5 kD and 14.0 kD and a MWCO of between 55 kD and 130 kD.